48 results
8-K
EX-3.2
PNT
POINT Biopharma Global Inc.
27 Dec 23
Termination of a Material Definitive Agreement
8:54am
dispute resolution mechanism, inquiry, investigation, administrative hearing or other proceeding, whether civil, criminal, administrative, arbitrative
SC 14D9
PNT
POINT Biopharma Global Inc.
13 Oct 23
Tender offer solicitation
7:11am
diligence investigation. Lilly’s confirmatory due diligence investigation continued through October 2, 2023.
On September 9, 2023, representatives
SC TO-T
EX-99
PNT
POINT Biopharma Global Inc.
13 Oct 23
Third party tender offer statement
6:52am
and meetings with POINT’s senior management and its representatives and outside advisors as part of Lilly’s due diligence investigation. Lilly’s … confirmatory due diligence investigation continued through October 2, 2023.
On September 9, 2023, representatives of Kirkland & Ellis LLP, outside counsel
SC14D9C
EX-2.1
PNT
POINT Biopharma Global Inc.
3 Oct 23
Written communication relating to third party tender offer
7:37am
) the FDA issuing one or more orders that impose a clinical hold on the investigation of the Company Products, the result of which would reasonably … be likely to result in a termination of, or a delay of 12 months or more in dosing patients in, the investigation of the Company Products (in which case
8-K
EX-2.1
PNT
POINT Biopharma Global Inc.
3 Oct 23
Tender and Support Agreement
7:35am
) the FDA issuing one or more orders that impose a clinical hold on the investigation of the Company Products, the result of which would reasonably … be likely to result in a termination of, or a delay of 12 months or more in dosing patients in, the investigation of the Company Products (in which case
ARS
rqebeke imvzkkr1mivi
1 May 23
Annual report to shareholders
1:52pm
8-K
EX-1.1
r97lgaom
14 Sep 22
POINT Biopharma Prices Public Offering of Common Stock
4:14pm
S-3
EX-4.6
jmh2wf
1 Jul 22
Shelf registration
4:13pm
S-3
EX-1.2
f0b8 3w8tzzda8tt
1 Jul 22
Shelf registration
4:13pm
S-3
EX-4.7
ie6ya4e583tkvyuq0v
1 Jul 22
Shelf registration
4:13pm
S-3
EX-5.1
n3yma5mm14k38n9
1 Jul 22
Shelf registration
4:13pm
424B3
qaqls 9gvx9l
31 Mar 22
Prospectus supplement
11:42am
POS AM
4iztyef9t
25 Mar 22
Prospectus update (post-effective amendment)
8:41am
424B3
z2t5anbgwf6enwt
5 Aug 21
Prospectus supplement
4:26pm
8-K
EX-3.2
1o4azkw4gvc
1 Jul 21
Unaudited pro forma condensed combined financial statements
12:00am